Ranibizumab for RVO: BRAVO, CRUISE, HORIZON

摘要

Introduction: Retinal vein occlusion (RVO) is currently the second cause of visual impairment due to retinal disease after diabetic retinopathy [1]. It is defined as a vascular disorder characterized by engorgement and dilatation of the retinal veins with secondary, mostly intraretinal hemorrhages, and retinal edema. Retinal ischemia, cotton wool spots, exudates and macular edema could also be present [2]. The incidence of vein occlusion is 0.7% for the age group 49 to 60 and 4,6% after 80 years old with no gender disparities [3].